AbCellera Announces The Federal Circuit Upholds Validity Of Its '408 Patent On Microfluidic Cell-Culturing Devices, Rejecting Bruker Cellular's Invalidity Challenge And Strengthening AbCellera's Position In Ongoing Patent Litigation.
There's No Escaping Bruker Corporation's (NASDAQ:BRKR) Muted Revenues
J.P. Morgan Maintains Bruker Corp(BRKR.US) With Buy Rating, Cuts Target Price to $60
Stifel Maintains Bruker Corp(BRKR.US) With Hold Rating, Cuts Target Price to $48
UBS Initiates Bruker Corp(BRKR.US) With Hold Rating, Announces Target Price $45
Bruker Is Maintained at Neutral by UBS
